SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup

By D. Stadlbauer, F. Amanat, Veronika Chromikova, Kaijun Jiang, Shirin Strohmeier, G. Arunkumar, Jessica Tan, D. Bhavsar, Christina Capuano, Ericka Kirkpatrick and 6 more. Current Protocols in Microbiology, 2020

688 citations recorded by the source corpus.

In late 2019, cases of atypical pneumonia were detected in China. The etiological agent was quickly identified as a betacoronavirus (named SARS‐CoV‐2), which has since caused a pandemic. Several methods allowing for the specific detection of viral nucleic acids have been established, but these only allow detection of the virus during a short period of time, generally during acute infection. Serological assays are urgently needed to conduct serosurveys, to understand the antibody responses mounted in response to the virus, and to identify individuals who are potentially immune to re‐infection. Here we describe a detailed protocol for expression of antigens derived from the spike protein of SARS‐CoV‐2 that can serve as a substrate for immunological assays, as well as a two‐stage serological enzyme‐linked immunosorbent assay (ELISA). These assays can be used for research studies and for testing in clinical laboratories. © 2020 The Authors. Current Protocols in Microbiology published by Wiley Periodicals LLC.

Subfields: Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/07d4cc6b6c938c9f98e4b001c7a4de9b4b8b6e4f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

Citations in the corpus

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals (2020, positive): “Veriﬁcation of SARS-CoV-2 exposure was attempted both by lateral ﬂow serology and SARS-CoV-2 spike protein receptor binding domain (RBD) ELISA (Stadlbauer et al., 2020), using plasma from the convales-cence stage blood draw.”
Comprehensive mapping of immune perturbations associated with severe COVID-19 (2020, background): “To evaluate the clonal landscape, we ranked the proportion of clones within the top ten (1-10), next 90 (11-100), next 900 (100-1,000), and most diverse clones with ranks above 1,000 (1,000+) (Fig.”